Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $10.82, for a total transaction of $21,640.00. Following the transaction, the president now directly owns 2,936,467 shares in the company, valued at $31,772,572.94. The trade was a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Trading Down 2.5 %

Shares of GYRE opened at $11.90 on Wednesday. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $30.39. The stock has a 50 day moving average of $12.83 and a 200-day moving average of $12.62.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Barclays PLC raised its holdings in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares during the period. Geode Capital Management LLC grew its position in shares of Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after buying an additional 43,840 shares during the last quarter. State Street Corp raised its stake in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after acquiring an additional 8,412 shares during the period. FMR LLC bought a new position in Gyre Therapeutics in the third quarter worth about $47,000. Finally, Advantage Alpha Capital Partners LP acquired a new position in Gyre Therapeutics in the third quarter valued at approximately $334,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.